More news – Page 2
-
NewsCARsgen wins first global approval of CAR T therapy for solid tumours
Approval of the autologous cell therapy satri-cel in China fills the gap in later-line treatment for advanced gastric cancer.
-
NewsPaulo Fontoura to lead research and development at Sanofi
Taking over from Dr Houman Ashrafian, the 25-year industry veteran will help to advance the firm’s innovation strategy.
-
NewsBiogen acquires immunology start-up RayThera for $1bn
Anti-inflammatory assets in the deal allow Biogen to expand immunology pipeline into new disease areas.
-
NewsFAP-targeted radiopharmaceuticals potential as next-gen treatment for multiple cancers
Innovative radiopharmaceuticals demonstrated “highly promising” survival benefit in study of participants with end-stage solid tumours.
-
NewsSandoz prepares for biosimilar ‘golden decade’ with new development centre in Slovenia
Opening of the new site represents the largest biosimilar development hub and supports Sandoz in building its in-house capabilities.
-
NewsRecipharm makes major investment to expand US sterile manufacturing footprint
Decision strengthens the CMDO’s fill-finish operations and increases capacity for biologics and advanced therapies.
-
NewsMHRA green lights lower dose EURneffy nasal spray for children
Needle-free allergy adrenaline treatment expands options beyond injection for younger UK patients for first time.
-
NewsPetri dish study could enhance accuracy of microbiological testing
Findings may help mitigate moisture-related issues when using Reasoner’s agar (R2A) during microbial water quality testing.
-
NewsMHRA targets medicine safety with new AI sandbox
Agency’s new AI initiative will provide an evidence-based programme to encourage pharmaceutical companies to invest in innovation in the UK.
-
NewsGSK advances oncology efforts with $10.6bn Nuvalent acquisition
Multi-product oncology deal accelerates GSK’s entry into lung cancer.
-
NewsGilead-MSD once-weekly oral HIV regimen meets Phase III endpoints
Combining islatravir/lenacapavir could provide alternative to daily antiretroviral therapy for virologically suppressed patients with HIV.
-
NewsRoche and Nurix to advance potential best-in-class BTK degrader bexobrutideg
Collaboration agreement expands Roche’s oncology pipeline and offers therapeutic potential across immunology and neurology.
-
NewsAmgen’s Imdylltra approved in Europe for aggressive solid tumour
Milestone authorisation represents the first T-cell engagement therapy for small cell lung cancer.
-
NewsCorrectSequence’s base-editing therapy shows preliminary success in sickle cell disease
Achievement of study’s primary efficacy endpoint positions therapy as potentially safer and more effective approach to CRISPR-based gene-editing therapies.
-
NewsEU Commission issues plan to replace animal testing in chemical safety assessments
Publication marks a significant step towards modernising chemical safety assessments in Europe.
-
NewsBiologics growth expected to reshape pharmaceutical packaging demand
Evolving regulatory requirements and ensuring product sterility and stability are driving demand for packaging innovation, particularly for biologic medicines, research suggests.
-
NewsLilly licenses Hanmi’s GLP-2 biologic sonefpeglutide for $1.2bn
Agreement to develop and commercialise long-acting GLP drug candidate by South Korea-based biopharma company.
-
NewsIdorsia’s glycan-targeting C diff. vaccine maintains positive clinical trajectory
Higher-dose cohort builds on earlier study data, positioning the synthetic glycan vaccine for future development.
-
NewsPfizer partners with Innovent for $10.5bn to advance ADC oncology medicines
Licensing agreement builds on Innovent Biologics’ earlier $11 billion collaboration with Takeda to develop novel ADC and immuno-oncology candidates.
-
NewsNovel CAR T manufacturing process significantly cuts production time
Efficacy findings comparable to those of existing CAR T cell therapies for relapsed/refractory multiple myeloma (r/r MM).